Hello, thank you for joining Healwell AI's 2024 fiscal second quarter financial results conference call. This call is being recorded. There will be a question and answer session at the end of the call, in which will be limited to analysts only. I would now like to turn the call over to Mr. Pardeep Sangha, Investor Relations at Healwell AI. You may begin. Hello, and thank you, operator. Joining me on the call today are Dr. Alexander Dobranowski, CEO of Healwell, and Anthony Lam, the company's CFO. I trust that everyone has received a copy of our financial results press release that was issued earlier today. Listeners are also encouraged to download a copy of our quarterly financial statements and management discussion and analysis once filed on SEDAR+. Please note, portions of today's call, other than historical performance, include statements of forward-looking information within the meaning of applicable securities laws. These statements are made under the safe harbor provisions of those laws. Please refer to today's press release and to our management discussion and analysis for more details on the company's risks and forward-looking statements. We provide forward-looking statements solely for the purpose of providing information about management's current expectations and plans relating to the future. We do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions, assumptions, or circumstances on which any statement is based, except if it is required by law. We use terms such as Adjusted EBITDA on this conference call, which is a non-IFRS and non-GAAP measure. For more information on how we define this term, please refer to the definition set in our management discussion and analysis. With that, let me turn the call over to Dr. Alexander Dobranowski, CEO. Thank you, Pav. Good day, everyone. We truly appreciate you for joining us today. I'd like to start today by providing a little bit of background on what is Healwell AI and who we are. Healwell AI is a health technology company focused on AI and data science for preventative care. Our mission is to improve healthcare and save lives through the early identification and communication of disease. Using our own proprietary technology, we are developing and commercializing advanced clinical decision support systems, also referred to as Co-Pilot technologies, that can help healthcare providers detect hundreds of diseases, including complex, chronic, rare conditions, improve clinical practice, and ultimately, and most importantly, help to materially improve patient health outcomes. Further to this, AI are able to unlock tremendous value for the life sciences industry by accelerating R&D efforts for therapeutic developments with a multi-tiered scientific research, real-world evidence, and clinical trials orchestration services. Why is our mission an important one? The earlier the detection, the greater the likelihood of treatment being successful. This is where artificial intelligence comes in. AI can structure historical patient clinical information to help inform physicians of markers and signals for potential disease in patients earlier, help driving to dramatically reduce time to detection. I'd like to now provide some key highlights from the second quarter. The second is an important continuation of our journey and embracing of our mission to revolutionize healthcare and improve patient outcomes through early disease detection. Healwell has now successfully launched its two-tiered business model of leveraging data science and artificial intelligence to support, one, healthcare providers with Co-Pilot technologies, and two, the pharmaceutical industry and their needs related to research and development and clinical trial orchestration. During the quarter, we achieved a significant milestone with the successful completion of our CAD 20 million equity financing source, mainly from long-term institutional investors. This capital infusion has notably strengthened our financial position, providing us with the necessary resources to advance our strategic objectives. This enhanced financial stability enabled us to consummate the acquisition of BioPharma and VeroSource, two pivotal moves that align seamlessly with our growth strategy. These acquisitions not only broaden our market, but also enhance our capabilities, positioning us for robust expansion and long-term success. We are confident that these strategic initiatives will provide substantial value and create new opportunities for our stakeholders. Last month, WELL Health announced Healwell participation in the Health Compass II project, the largest digital initiative to date. This project is supported by CAD 15.3 million in funding over four years, and as part of this initiative, Healwell AI's Decision Compass module will play a pivotal role in enhancing early diagnosis and care for rare and complex diseases through an advanced AI technology. This collaboration not only underscores Healwell AI's commitment to enhancement through AI and interoperability, but also demonstrates our dedication to benefiting providers and patients across Canada. With regards to AI credibility, we shared numerous world firsts of validation with regards to our AI capabilities, namely with research produced from our subsidiary, Pentavere, receiving peer-reviewed validation from some of the most prestigious medical journals globally. Highlighting our groundbreaking work in oncology and other specialties, I'd like to congratulate the Pentavere team for this groundbreaking work in artificial intelligence. Our acquisition pipeline remains exceptionally strong, positioning us for substantial expansion. We anticipate that our strategic acquisitions will drive us to achieve a figure that is approaching a CAD 100 million revenue run rate by year-end, building current run rate, which already exceeds CAD 65 million. This also sets up our profitability objective, and we are already providing guidance that we will reach profitability on an Adjusted EBITDA basis by next year. Before I hand the call over to Anthony, our CFO, I'd like to continue today's call by providing some commentary on three key topics. One is our mergers and acquisitions activity. Two, the launch of our four AI Co-Pilots. And three, incorporating artificial intelligence across all our businesses. I'll now expand on our first key topic, our mergers and acquisitions activity. Healwell is executing a strategy centered around developing and acquiring technology and clinical sciences capabilities that complement the company. From a corporate development perspective, Healwell is targeting AI and data science companies that expand current early disease detection capabilities and mature operating healthcare software, Digital health, and clinical research companies that provide access to additional clinical information and profitable, mature, recurring revenue. These latter targets are also suitable to be ameliorated with our current AI capabilities. I'll expand on this further in just a moment. Since our debut in October 2023, we've made four notable acquisitions: Pentavere, IntraHealth, VeroSource, and BioPharma. Having previously discussed Pentavere and IntraHealth, today I'll focus on VeroSource and BioPharma. We are thrilled to welcome these two companies to the Healwell family. On July 1st, Healwell acquired VeroSource, a healthcare technology software company, which provides us with a number of unique capabilities for the public sector, including digital front and access solutions, international patient summary solutions, and FHIR interoperability. VeroSource provides a VSG, which is an end-to-end customizable cloud-based solution that enables clinicians and decision-makers to seamlessly access and work with healthcare data, providing customers with a range from integration systems, adoption with right-fit cloud services, advanced enterprise resource planning and IT strategy. VeroSource is a very important addition to the Healwell group of companies and cements our ability to provide value for a very important key stakeholder, the public sector. CEO Mark McAllister and his team have done a tremendous job building VeroSource. On July 1st, Healwell also acquired BioPharma, led by Managing Director Anna Taylor, a leading full-service CRO contract research organization specializing in early-phase clinical trials, thereby significantly enhancing our clinical research capabilities, enhancing our existing operations through our subsidiary, Canadian Phase Onward. BioPharma is dedicated to advancing medical science to improve the lives of its patients by bringing pharmaceutical products to the market through high-quality medical research, uses state-of-the-art facilities and scientific expertise to provide customers with clinical trial services, along with a full suite of support and laboratory services. Now, BioPharma is an especially strategic acquisition for us, given how substantial the CRO marketplace is globally and the potential to digitize and AI-enable such assets. We're in the early stages of thinking of this in a manner that is an analogous WELL consolidation and digitization of healthcare clinics. These are profitable and resilient businesses that have been around for a long time, but have not benefited from technology as much as one would think. The main role of CROs is to orchestrate clinical trial activity and help pharmaceutical companies execute on their research and development goals. All the while, it is clear that most CROs are extremely under-digitized. We believe this is a market opportunity for us, especially given how our AI technology can help detect disease early and find patients, which is one of the most important aspects of our business. When you combine our capabilities to find patients, coupled with our strategic partner, WELL Health's enormous clinical data, we have something here that we believe could be globally unique and valuable. Both acquisitions are expected to be financially, quickly accretive, significantly enhancing HEALWELL's financial profile and core capabilities. This includes comprehensive data science offerings for enterprise clients such as the public sector, and expanded clinical research services for the pharmaceutical industry. Our revenue CAD 65 million, and we are strategically positioned to achieve a target run rate figure approaching CAD 100 million by the end of the fiscal year. We are highly optimistic about our future trajectory, driven by a combination of organic growth and opportunistic acquisitions. Now, the 4 acquisitions to date have positioned the company to unlock power, the power of health data and artificial intelligence for 3 key stakeholder groups. 1, clinicians in healthcare clinics with Co-Pilot offerings. 2, large enterprises such as Canadian provincial healthcare system, with interoperability, population health and related services. And 3, the pharmaceutical industry with a multi-tiered offering that includes research, real-world evidence, and clinical trials orchestration services. In addition to these recent acquisitions, we acquired the remaining 20% ownership interest in MCI Polyclinic Group, eliminating a CAD 1.3 million put option liability, positioned for growth. We completed an investment of $2 million in xAI, an artificial intelligence company founded by Elon Musk. The investment was made indirectly through Think 1st Principles investment vehicle, and through this investment, Healwell has gained access to the xAI developer program, allowing us to leverage the world-leading technical and AI-oriented expertise and resources of xAI. I will now expand on our second key topic, the launch of four AI clinical Co-Pilots. As we continue to expand our AI capabilities at Healwell, we are building a platform that can help screen and identify patients at risk for rare, complex, and chronic diseases. This platform will support clinical decision-making across all clinical domains, embodying our vision of advanced clinical decision support. As we acquire and build out these capabilities, we'll be continuing to launch in parallel what we call physician Co-Pilots. As of the end of July, Healwell has launched four advanced AI Co-Pilots, each targeting a specific clinical domain to improve patient care outcomes. This is an important part of our thinking of how best to build value in AI and healthcare. The first Co-Pilot is focused on rare diseases. Rare Disease Co-Pilot, developed under Khure Health and white labeled as WELL AI Decision Support, has been upgraded to its second generation. This enhanced tool aims to improve diagnosis and management of rare diseases by providing specialized clinical insights, thereby offering more accurate patient care for patients. The second Co-Pilot, Chronic Kidney Disease, is HEALWELL AI's Co-Pilot technology integrated with WELL AI Decision Support, now features advanced chronic disease screening capabilities. This tool focuses on enhancing CKD management, providing actionable insights, and improving patient risk stratification, which could significantly reduce the economic burden of CKD. Our third Co-Pilot, Oncology. HEALWELL AI's subsidiary, Pentavere, in collaboration with Sunnybrook Health Sciences Centre, has introduced with DARWEN AI, a clinical Co-Pilot that enhances cancer diagnosis or complex cancer. This innovation, demonstrated in a prestigious publication, a world first of harnessing AI to improve oncological decision-making through better automation and accuracy in cancer staging. The fourth is Cardiovascular Disease. HEALWELL AI's latest Co-Pilot for cardiologists, launched in partnership with WELL Health, is designed to enhance the early identification of patients at high risk for cardiovascular disease. Deployed across WELL diagnostic centers, this technology aims to improve early diagnosis and patient care while supporting HEALWELL in advancing CVD-related research and expanding business opportunities. Looking towards the future, you can picture HEALWELL AI capabilities rapidly growing through the acquisition of targets, as I mentioned in the first category, building out the foundational platform of advanced clinical support, and then we'll be deploying these technologies into our partner healthcare systems like WELL Health and also into our own platform. We believe this is quite a compelling strategy. Lastly, I will now expand on our third key topic: incorporating artificial intelligence technologies across all our businesses. One of the company's main strategic initiatives is to integrate its current AI early disease detection capabilities into assets that are acquired, essentially using AI to level these. Not only does this materially enhance these assets, products, and offerings, but also opens up new commercial value and opportunity. To do this properly requires careful planning and execution. We have already advanced the process of bringing these technologies into our subsidiary, IntraHealth. In addition, we've also begun the process of both of our latest acquisitions, VeroSource and BioPharma. In the case of IntraHealth, our intention is to fully embed our AI tooling and capabilities right into the core of the EHR, building what we call a next generation EHR. And as I mentioned, with regards to BioPharma, we see a very compelling opportunity leveling up the CRO space, as AI can readily add compelling value with regards to accelerating patient discovery, improving clinical trial infrastructure, and unlocking tremendous efficiency within the multi-phase clinical trial R&D process for life sciences. Next, I'll provide additional details on the company's outlook, but first, I'd like to hand it over to our CFO, Anthony, who will review the financial results for the second quarter of 2024. Thank you, Alex. Before I get into our second quarter results, I want to mention that all the figures are quoted in Canadian dollars, and our financial statements are prepared in accordance with IFRS. Okay. As we look at Q2, it's important to note that our Q2 results do not fully reflect the company's current run rate revenues, over CAD 50 million. The VeroSource and BioPharma acquisitions finalized in July and are anticipated to contribute to our increased revenues and improving profitability in the second half of the year. Looking forward, we're optimistic about the best costs for both our top and bottom-line performance. I'll now turn to our second quarter 2024 results, which are as follows. These are all from our continuing operations. Healwell achieved quarterly revenues of CAD 5.44 million during the second quarter of 2024, compared to revenue of CAD 1.79 million generated during the same quarter last year. Revenue growth was primarily driven by the acquisition of IntraHealth, with additional contributions from Khure, MCI Poly and Pentavere. Healwell achieved gross profit of CAD 3.31 million in Q2 of 2024, compared to CAD 331 thousand during Q2 of 2023. The increase is mainly driven by the acquisition of Pentavere and IntraHealth. Healwell's gross margin percentage in Q2 of 2024 was 71%, and this compares to 19% in Q2 of 2023. The increase in margin percentage was due to the acquisition of IntraHealth, Khure, and Pentavere. During Q2 of 2024, Healwell reported adjusted EBITDA loss of CAD 3.68 million, and this compares to an adjusted EBITDA loss of CAD 9.89 million in Q2 of 2023. The improvement was driven by reduced operating expenses and the elimination of loss-making clinic operations, coupled with an increase in revenues to produce improved results over the comparable periods in 2023. Healwell reported CAD 2.54 million in net income in the quarter, as compared to a loss of CAD 9.81 million in Q2 of 2023. This was primarily due to the successful removal and settling of a significant number of liabilities, offsetting of a number of significant settlements incurred in the previous years. I will now provide an update on our cash and position. We ended the quarter on June 30, 2024, with CAD 19.8 million in cash. Cash increased to CAD 19.82 million from CAD 11.34 million at the end of Q1 2024, largely due to a CAD 20 million dollar financing and the receipt of an additional CAD 8.8 million from the exercise of in-the-money warrants. We reduced our liabilities by approximately CAD 15.5 million in Q2 2024 by extinguishing of payment obligations related to legacy MCI Medical Clinics business and receiving CAD 7.9 million in loan forgiveness from the First Canadian Wellness Company. So we've now significantly reduced debt to CAD 13.2 million in convertible debt debentures, loans, excluding earn-outs on our acquisitions partners. It's important to stress that a significant portion of our convertible debt is expected to be at favorable prices, potentially extinguishing another CAD 10.1 million in debt and resulting in approximately CAD 1.5 million post-conversion. If all of Healwell's outstanding in-the-money warrants were to be executed, our cash balance would grow to approximately CAD 45 million. With our robust financial position and reduced liabilities, we are confident in our ability in executing our strategic initiatives and delivering value to our stakeholders. I want to spend a few minutes now talking about our revenue segments. The company generates revenue in three distinct segments. First, AI and data science. Second, we have a healthcare SaaS business, and third, we have clinical research patient services. Looking at AI and data science, which is anchored in the integration of cutting-edge artificial intelligence technologies within the healthcare landscape through technology-enabled rare and chronic disease screening from its Khure Health and Pentavere. Leveraging state-of-the-art AI algorithms and advanced analytics, Healwell analyzes extensive clinical data to extract invaluable insights. These insights are then transformed into actionable recommendations. With early disease detection capabilities, this proactive approach optimizes the patient pathway, ensuring swift and accurate diagnosis and treatment. The segment experienced an impressive 261% growth this quarter compared to the same period in 2023. Our AI and data science serves a clientele of life sciences, pharmaceutical, medical device, and precision medicine companies. I am proud to announce that we signed 6 MSAs, or master service agreements, with pharma and life sciences companies in Q2, bringing the total number to 22 signed MSAs, including both Khure Health and Pentavere. The recent commercial success highlights Healwell's growing reputation and compatibility with healthcare and life sciences industries. The number of new MSAs signed in the quarter can be lumpy, as a signed MSA does not necessarily translate to immediate revenue, but rather it is a leading indicator of the size of our pipeline for future revenue-generating opportunities. Most importantly, our success in signing MSAs with large pharma and life sciences companies is a good measure of our growing credibility in the industry. Our second revenue stream is health software as a service. Revenue provided by IntraHealth, an enterprise-grade EHR platform. IntraHealth's clientele of healthcare providers, hospitals, and clinics, and its extensive network of over 15,000 healthcare service providers across multiple jurisdictions, spanning Canada, Australia, and New Zealand. IntraHealth's SaaS-based model has historically yielded over 80% gross margins alongside positive EBITDA and cash flows, with a significant portion of revenue deriving from high-margin recurring sources. This segment generated CAD 2.1 million revenue in Q2, a significant increase from 0 revenue in the same quarter last year. With the addition of VeroSource, we expect the segment to grow to further Q3. Now turning to our third revenue segment, patient services, which consists of research delivered by Canadian Phase Onward, Healwell CRO, providing life science research services, and the revenue consultations delivered through the company's Polyclinic group in Ontario. Clinical research is our contract-based revenues. This segment operates as on a per visit or project basis and has a track record of EBITDA. It also caters to diverse clientele, including government reimbursement, health, health insurance reimbursement, and research sectors. The segment experienced 27% growth in revenue this quarter compared to the same period in 2023. The addition of BioPharma, we expect this segment's revenue to grow even further in Q3. To note, does have some seasonality as the summer months do typically feature less clinical trials activity and does speed back up in Q4. The second half of the year, we expect approximately 60%-65% of BioPharma's revenue to come in Q4, while 30%-35% of BioPharma's revenue to come in Q3. In summary, I'm pleased that Healwell's outlook is bright and is strong, and in a strong financial position, and has capital to fund future acquisitions and execute on organic growth initiatives. I'll now turn the call back over to Alex. Thank you. I'll now provide some additional detail on our strategy. It is our view that this is a very special time in healthcare, especially with regard to artificial intelligence. These technologies are still very novel, and in healthcare in specific, we are at the beginning stages of likely become one of the largest sector transformations in history. But how do you win and build tremendous value leveraging AI and emerging, emerging technologies in healthcare, especially when these technologies are in the very early days of gaining commercial traction? We believe the only way to build durable and sustainable value in, in healthcare AI is by executing against a strategy of growth as we have articulated. We are building a company that not just has globally validated in production AI, but that also acquires high-quality assets, profitable, highly recurring revenues and sustainable growth opportunities. This will position Healwell exceptionally to capture value as the entire artificial intelligence market in healthcare continues to rapidly mature and grow. As mentioned, Healwell generates highly recurring revenue via our healthcare SaaS business line, and we serve over 250 pharma customers through our AI and data science research offerings. This is durable revenue generated from high-quality customers. I'll now provide more details on our M&A pipeline. In terms of our future acquisition pipeline, we have a very full and active pipeline of acquisition opportunities. We are currently looking at numerous compelling acquisitions that fall into two categories. First, our healthcare AI and data science companies that have capabilities and are focused on early disease detection across all clinical domains. These types of targets are now starting to demonstrate real revenue traction and achieve validation that their technology works safe and compliantly. This is a very exciting time to be targeting AI-oriented healthcare companies. Companies with these types of capabilities simply did not exist even a few years ago. Pentavere is an excellent example of the kind of companies we are targeting. The second category of acquisition targets are mature operating companies with strong financial profiles that would be vertically integrated with our AI technologies to drive incremental revenue, cash flow, healthcare software companies such as EMR, EHR, clinical research companies, and also Digital health companies are good examples. These types of companies provide us with a vector of access to more patient providers and clinical information, but also importantly, have a very strong profile from a financial fundamentals perspective, with maturing revenues, positive EBITDA, and free cash flows. IntraHealth and BioPharma are excellent examples of the kinds of companies we are targeting in this second category. Now, from an outlook perspective, we are strategically positioned to achieve a target revenue that is approaching CAD 100 million by the end of the fiscal year. As a reminder, just 10 months ago, when Healwell debuted, our revenue was just over CAD 7.5 million. This ambitious goal reflects our robust growth trajectory, fueled by successful acquisitions and a strong pipeline of new business opportunities. We also believe our forecasted revenue levels put us in a strong position to be profitable on an EBITDA basis next year, which is something we're very committed to. This growth and progress is underpinned by our continued focus on creative capital allocation as well as organic growth, especially as we ramp up physician adoption of the Healwell platform, accelerating the sales of our AI tools and technology, and broadening our reach within the WELL Health ecosystem. We are seeing unprecedented opportunities in healthcare and health data science and AI, and our advanced AI Co-Pilot technology is at the forefront of this evolution. Our commitment to enhancing healthcare delivery, innovative technology remains unwavering, and we are poised to capitalize on these opportunities to drive substantial value for our stakeholders. Now, beyond M&A activities, our key, key areas of focus continue to include ramping up physician adoption of the platform, deepening our integration within the WELL Health ecosystem, accelerating sales of our AI tools and technology under the Khure Health and platforms, adding new commercialization agreements in partnership with life sciences companies, health systems, and other commercial partners, broadening the reach of our IntraHealth EHR through adding AI capabilities. We have an extremely positive outlook based on our organic growth and our M&A strategy. I'm excited by the immense potential for growth and innovation, particularly in the realm of AI technology. Healwell aligns perfectly with this trend. Now, in closing, I wanted to reiterate that Healwell is a healthcare AI data science company that has proven results in revenue from 6 of the top 10 largest pharma companies. The WELL Health relationship accelerates our exclusive access to providers across North America. We have notably strengthened our financial position, providing us with the necessary resources to execute on our strategic objectives. M&A will play a significant role at Healwell. We have already completed 4 transactions, VeroSource and BioPharma being 2 of the most recent. We are well capitalized and will continue exploring acquisitions that further Healwell's strategy. We believe that we have the necessary building blocks in place to successfully execute in healthcare AI. Time is now to plant our flag as a leader in healthcare AI and execute against this mission. Finally, I want to thank the entire Healwell team, whose hard work continues to elevate the company to higher levels. I'd like to thank our investment banking partners. I would like to thank Hamid and the leadership team at WELL Health. I'd like to thank my board of directors. Also, I'd like to thank all of you for joining us on the call today. We look forward to providing an update next quarter. I'll now hand it back to the operator. Thank you. Ladies and gentlemen, to ask the question, please press star one one on your telephone and then wait to hear your name announced. To withdraw your question, please press star one one again. Just a reminder that questions will be limited to analysts only. Please stand by while we compile the Q&A roster. Our first question comes from the line of Christian Sgro with Eight Capital. your line? Hi, good evening, and thanks for taking my questions. I just wanted to start broadly on physician trends and uptake of the clinical decision support platform. You know, what color could you provide contextually on, you know, uptake in Canada and abroad, on the platform in terms of onboarding and then, you know, usage and feedback from doctors at this stage? Very nice to speak to you, and thanks so much for the question. So there, there's kind of two areas you can look at, at, at uptake, right? One is through our most important partner, right, which is, which is WELL Health and that ecosystem. And two is also through the outside of WELL Health, which is mainly done under our subsidiary, Pentavere, which is work with hospitals both in Canada, and U.S. Now, we're and Christian, you know, just to highlight, part of the, the structure of the relationship with WELL was making sure that we actually solve for you know, some of the important points of, of adoption. And as we know, it can be difficult, right? I'm a physician, so I can say that, right? Physicians are busy, they're stressed, they're not always available, right, to use new tools or new technologies. But because of the way that Hamid has built WELL Health, right, the cultural side of WELL Health, the willingness to resource the adoption of new technologies and the years of track record, right? Successfully digitized clinics, has successfully introduced new technologies, right? Healwell is able to piggyback off that success. So at Healwell, we have a dedicated team that works directly with physicians within the WELL Health ecosystem, and had no traction with onboarding physicians and very strong feedback, including also feedback directly from the Chief Medical Officer of WELL Health. So that's a bit of color, Christian, on how that's going. But it takes time, right? Like, we have a very ambitious plan and an ambitious vision. Perfect. Thank you for all that additional color. The second question I've got, now Anthony referenced the 6 MSAs signed in the quarter. And that sounds like a lot in a 3-month span. But just maybe so, I know we understand the MSA is the starting point. Revenue recognition will come as work is performed. But could you maybe lay out just what the typical MSA would entail? That my understanding would be it opens the doors to, you know, projects for different research projects or therapeutics or that, but really sets the stage, you can start working on a more fluid basis. Does that sound correct? And anything else you could share to clarify would help. Thank you. Yes, sure. And look, we called out that number because that is actually quite an accomplishment, right? To develop six net new relationships with life sciences companies in parallel. And to get to that position, right, you've worked through all of the rigmarole around compliance, right? Around just the legal aspects of each vendor, right, on these types of initiatives. And I think this is a really strong signal of credibility, number one. Number two, you don't typically go through the work of putting together one of these master services agreements if you're not serious about taking the next step to put it together commercially. So historically, right, if we have an MSA, there's been a 100% conversion to commercial work together. So look, we're right now, right, we're getting these relationships in place, so then we can really, really focus and build on the revenue opportunity, right? So in coming quarters, we'll be highlighting, okay, well, what does that track look like? Perfect. Thank you for taking my questions today. Thank you, Christian. Please stand by for our next question. Our next question comes from the line of Allen Klee with Maxim Group. Your line is open. Hi. Could you just remind us, you said for Co-Pilot, there were four areas you were targeting. Could you just state what those four were? I missed one of them. Thank you. Yes, of course. And Alan, it's good, it's very good to see you. So look, since Healwell debuted, we've successfully launched, right, in production, for AI clinical Co-Pilots. And all of these Co-Pilots, they support physicians in this mission of early disease detection. Okay, so that's the context, like, what do these Co-Pilots actually do? So they're able to work in the background, screen clinical information, and flag patients that either have gaps in care or are at high risk of certain conditions. And the first Co-Pilot we launched, which is really a result of the IP that's been developed over a number of years in our subsidiary, Khure Health, is our rare diseases-oriented Co-Pilot, which WELL Health then adopted, labeled as WELL AI Decision Support. So that then screens for rare and ultra-rare conditions. The second Co-Pilot we launched, also as part of the result of the hard work under Khure Health, is our Chronic Kidney Disease Co-Pilot, which screens now—So now this is demonstrating that we don't just have Co-Pilots that can find patients with rare diseases, but also with chronic diseases. Chronic kidney disease, in particular, is a disease of enormous burden in the general population, and this also has been launched and also has been integrated into the WELL AI Decision Support system. The third Co-Pilot, Alan, is our Oncology Co-Pilot, and this Co-Pilot was developed under our subsidiary, Pentavere, which collaborated with one of the most important hospital groups in Canada called Sunnybrook. And this Co-Pilot actually has just incredible capability, where it's able to enhance the accuracy of cancer staging for really complex head and neck cancers. As a result of this technology development, Pentavere also published research, which was a world first of using generative AI in this type of a capacity. So really, really compelling technology. And that is focused on cancer and improving cancer staging. And then the fourth, our most recently launched Co-Pilot, is one that's focused on finding patients with gaps in care or at high risk of cardiovascular diseases. So this is a cardiology-focused Co-Pilot, which again, was launched in partnership with WELL, because WELL Health has a very large cardiology diagnostic network called MyHealth, and that's where we've launched our Co-Pilot. So these are our first four, and going and looking towards the future, Alan, we're going to be launching Co-Pilots in additional clinical domains, right? So that, that's a really important of our AI strategy. ... Thank you. Thank you. My last question is, what would you say were the main factors affecting change in sequential revenue? And in terms of the Adjusted EBITDA that you posted this quarter, what are the - do you think that you haven't - you did provide that you believe Adjusted EBITDA could be positive in 2025. Is there any commentary on sequentially how that might move from this quarter to throughout 2024, if it might go up wider or narrower? Thank you. That's a great question. Thanks. First, I'll start with the kind of revenue piece. And, you know, we saw some good, strong revenue generation from our existing businesses in Pentavere and Khure. So that, you know, that was definitely, you know, just some of our in-house business already growing with IntraHealth this year as well, and seeing a full quarter of IntraHealth was really what bolstered our top line revenue number. So that, we can continue to expect to flow through the rest of our fiscal year. In terms of our, you know, EBITDA, our EBITDA that we saw this quarter is something that I would say, you know, as we look at the addition of VeroSource and BioPharma, they will have a big impact on our top line and our EBITDA performance. I will bring your attention to the fact that while we will expect, you know, strong results from both those institutions, the third quarter is typically a slower quarter from a clinical research perspective. And so the impact from the BioPharma will, I would say, you know, a certain impact than in our fourth quarter. And so if we were talking about how to think about our business in the upcoming second half, you know, growth from having both those two additions in there. But I would say that any marked change in our EBITDA will likely be in the fourth quarter versus the third quarter. So our third quarter will likely look very similar to what we had in the second quarter, with marked changes showing up in our fourth quarter. Thank you very much. Thank you. Please stand by for our next question. Our next question comes from the line of Justin Keywood with Stifel. Your line is open. Good afternoon. Thanks for taking my call. Certainly sounds like several growth opportunities to go after. Maybe just coming back on the actual Q2 results, and I'm not sure if I missed this, but what was the actual organic growth contribution? Thank you. Organic? That's a great question. Thanks. Organic contribution from Pentavere, Khure, and IntraHealth was quarter-over-quarter. I'm sorry, the line may have cut out there for a second. What was the number? It was a full change that you saw in our numbers because we didn't with IntraHealth, Pentavere, Khure, they were all in our organization in Q1. And so what we had from a Q1 to Q2 move in our top line revenue was all organic. Okay. All right. Thank you. That's clear. All organic. Yes. Yeah. And then on the outlook and expanding the sales run rate from CAD 65 million to CAD 100 million by year end, and assuming that's gonna be M&A driven, and just given the current composition of Healwell's revenue with the AI data science, healthcare, and SaaS, and then the CRO, how will that composition shift in meeting that CAD 100 million-dollar run rate goal? And any color around that would be appreciated. Sure. Sure, Justin, thank you for the question. And I think, you know, a little bit of color I can provide, right, is we're in very advanced discussions with targets in those two distinct categories, right? The first category being AI-oriented, early disease detection companies, right? They're just starting to get revenue traction. Very, very exciting, validated technology. And then also, we have very big discussion with companies in that second bucket, right? These are the mature operating companies, right, that are focused on healthcare, clinical research, digital health. So you're gonna see a mix. Now, on the AI side, right, these companies are smaller. They don't have, you know, staggering revenue yet. But Justin, what's going to start shifting the composition of that revenue is when you vertically integrate, right, with this AI capability and unlock additional commercial value from AI-oriented capability. So, you know, that's probably the color I can give you at the moment. I appreciate that. Yeah. Maybe what I'll add, for just a little color here, I think, are you asking about our segments and what we can expect in our segments longer run, in terms of revenue contribution? Is that, is that your - is that what your question is? Yes, essentially. ... I mean, as we get to the tail end of this year and in, you know, we dial into where we are gonna be next, you know, this time next year, I think if you look at our AI and data science business, you'll think about that as 10% of our revenue mix, you know, over the next 12 months. In terms of our health, our healthcare software SaaS business, we're gonna be, call it, call it 30%. And then, and then our clinical research business would likely make up 60% of our business, so give or take. But that means segments as we go ahead right now with our current roster of, of, businesses. Appreciate that. Maybe just one follow-up on the M&A pipeline. Should we expect similar transactions as far as size, you know, VeroSource and BioPharma, or are there kind of broader tuck-in opportunities and maybe some transformational? If you could just describe the composition of the M&A pipeline. Thank you. Well, Justin, because there's such a difference between markets, look, we are looking at and maturing discussion with targets of, you know, the whole spectrum of size, everything from smaller companies that have this, you know, incredibly, you know, validated AI technology all the way to even transformational type of size bracket. Thank you for taking my questions. Thank you, Justin. Thank you. Please stand by for our next question. Our next question comes from the line of George Ulybyshev with Clarus Securities. Your line is open. Good evening, guys, and thanks for taking our questions. Just a couple of questions here on my end. With respect to your M&A goals, are you guys actively exploring any acquisition opportunities south of the border, or are you primarily focused on Canada at the moment? George, thanks so much for your question. Look, to answer that, we, you know, we believe the technology and capability that we have in house today, right, can materially improve healthcare, you know, not just in Canada, but in other jurisdictions. So to answer your question, we are looking at opportunities both, you know, Canada, in the US and also in international jurisdictions. Got it. Got it. Thanks, Alex. And just one more. Can you elaborate a little bit on your growth strategy for VeroSource going forward and as well as any potential synergies that you hope to extract from the acquisition? Sure. Yeah, and George, VeroSource, you know, they've just built a real phenomenal company, and they've successfully commercialized into four jurisdictions, four provincial bodies. And I think one of the important synergies is that with the HEALWELL capability and also through the WELL Health partnership, right, can we open doors in new provinces under VeroSource or in, and also other jurisdictions? So that, I think, is gonna be one of the big kind of value adds that we bring in our partnership with VeroSource. And I think that's something that's gonna be very, very exciting because they've already demonstrated these capabilities and delivery of a really quality product to the provinces where they currently work commercially today. Got it. That's it from me. Thanks, guys. Thank you, George. Please stand by for our next question. Our next question comes from the line of Gabriel Leung with Beacon Securities. Your line is open. Hi, good afternoon, and thanks for taking my questions. Alex, are you able to provide us with any early feedback from some of your provider partners on how they're liking or using the early decision support tools? I guess it would be primarily within the WELL Health clinic. I'm just curious what feedback, positive or negative, you're getting from those providers. Sure. And Gabriel, you know, on a higher manner, right, we've been working with hundreds of physicians over the years now, the last couple of years, outside of the WELL Health ecosystem. So we have a pretty strong set of testimonials, and we've worked in quite a bit of feedback during that time. I think I'll just highlight that, you know, Dr. Michael Frankel, the Chief Medical Officer of WELL Health, a few months ago, right, we were able to sit down and work with him and be able to actually screen his patient population. And I think, you know, part of the exciting that we did with him was he saw, okay, this technology, right, is. It works, and he was able to find important insights and flag patients, right, that then he was able to take action on. And just to segue to that, Gabe, as I'm giving more of the positive feedback, right, is part of the work that we've done and that we talked about with regards to digital and, right, our technology was demonstrated by the WELL Health Medical Leadership Team to the Minister of Innovation a few weeks ago. So look, on the spectrum of feedback, right, the feedback we received is largely positive, right? We're seeing incremental steps being taken with regards to adoption. That's really important because, you know, adoption of technology in healthcare is really hard. So, Gabe, it's been very positive. ... Got it, you know, thanks for that. I just have two questions for Anthony. First, can you talk a little bit about how, based on your current base of assets, whether we should expect any sort of seasonality around free cash flow, number one? And number two is, you know, obviously, you've acquired a bunch of assets. There's gonna be a lot of integration happening now. What are some of the top integration tasks that you're gonna be addressing over the near term? So great question. Okay, so we'll start off with the cash seasonality. I would say, I think we're at a point now where we really have, and really look at, you know, some of these really operating at some level of maturity here. We're seeing that the cash will line up really well with our EBITDA, our adjusted EBITDA number. So as you look at us moving ahead, you know, our cash source and use will follow that line item. And in terms of then integrating, you know, new opportunities, and we're going through this right now with VeroSource and BioPharma, is really creating systems where actually in one case, you know, helping out with a lot more from an and actually, you know, business operations perspective than the other. And so we really are looking at each one individually as to what they need individually, providing the support levels that maybe they were lacking in certain areas and really helping them, you know, focus on their business growth rather than just the administrative stuff. So from an integration perspective, just improving systems, bringing better technology to where they have to help run their administrative functions. And where possible, we're integrating suppliers as well. Got it, you know. Thanks for all the feedback, guys. Yep, thank you. Please stand by for our next question. Our next question comes from the line of Rob Goff with Ventum Financial. Your line is open. Thank you very much for taking your questions, guys. Hey, thanks, Rob. Good to speak to you. Yeah, Alex. So Alex, you've talked a bit about Co-Pilots, the four projects. Can you talk to your expectation of is that four going to 10, or is it four getting deeper? Just sort of manage our expectations in the cadence of additional programs versus going broader and deeper within the four. Yes. So Rob, great question. This is important, right, in the clinical nuance. So I did mention that in particularly the first Co-Pilot we launched and highlighted our Rare Disease Co-Pilot, we did update it to its transformation, right? That's capability to screen for even more rare and ultra-rare conditions. So to answer your question, Rob, we are to end with new Co-Pilots because there's... They're really interesting, clinical domains, right? Which we just don't have any of this yet. You know, one particular area that's of keen interest, right? Dermatology, for instance, that's got a big burden in primary care. We're looking at Co-Pilot technology in separate domains. And then we're also focused on building out the depth and capability of our current Co-Pilot. So you're gonna see a mix of attention and resourcing to both those vectors, right? Where we will add new additional Co-Pilots, but we'll also be expanding the current offerings, roughly balanced, Rob. Okay, thank you. And you, you had talked about the CRO business being a target for acquisitions. Can you talk to your view of the targets? Like, are there opportunities where smaller, CROs have not fully digitized so that, you know, part of your value equation is to accelerate that digitization? Yes. So, Rob, this is a really exciting theme. So, we have technology, right, that can screen and find patients that are at high risk of certain conditions. And in the same technology, we can screen and find patients that are of high eligibility for certain different clinical trials. And that's a massive pain point of the industry of the entire life sciences, is just finding enough patients that meet the eligibility criteria. So, we can really enable that. So to answer your question, there are, well, first of all, the CRO space and just in North America, the industry is absolutely staggering in size. And look, there are CROs of the entire spectrum, right? Many which are technology antiquated, so many are technology upgraded, but many or most don't have the capabilities that we've developed from a stratification perspective. So we see a lot of opportunity in expanding right off this anchor that we have with pharma and Canadian Phase Onward and growing rapidly in the clinical research space. Thank you very much, and good luck. Thanks, Rob. Thank you. Ladies and gentlemen, I'm showing no further questions in the queue. I would now like to turn the call back over to Alex for closing remarks. Thank you, operator. In closing, I want to thank everyone once again for joining our call today. Thank you to the analysts for their questions. Everyone, please stay safe and healthy. We look forward to providing more updates in the future. Thank you. Ladies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect.